At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Subscribe To Our Newsletter & Stay Updated
